vs
Side-by-side financial comparison of Inhibikase Therapeutics, Inc. (IKT) and ScanTech AI Systems Inc. (STAI). Click either name above to swap in a different company.
Inhibikase Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $631.0K, roughly 1.6× ScanTech AI Systems Inc.). Inhibikase Therapeutics, Inc. runs the higher net margin — -1223.3% vs -1532.9%, a 309.6% gap on every dollar of revenue.
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
IKT vs STAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $631.0K |
| Net Profit | $-12.7M | $-9.7M |
| Gross Margin | — | 27.6% |
| Operating Margin | -1323.3% | -773.2% |
| Net Margin | -1223.3% | -1532.9% |
| Revenue YoY | — | — |
| Net Profit YoY | -5.0% | — |
| EPS (diluted) | $-0.10 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | — | ||
| Q3 25 | $0 | $631.0K | ||
| Q2 25 | $0 | $884.0K | ||
| Q1 25 | $0 | $346.1K | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
| Q4 25 | $-12.7M | — | ||
| Q3 25 | $-11.9M | $-9.7M | ||
| Q2 25 | $-9.9M | $-6.9M | ||
| Q1 25 | $-13.7M | $-17.9M | ||
| Q4 24 | $-12.1M | — | ||
| Q3 24 | $-5.8M | — | ||
| Q2 24 | $-5.0M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 27.6% | ||
| Q2 25 | — | 14.3% | ||
| Q1 25 | — | 29.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -1323.3% | — | ||
| Q3 25 | — | -773.2% | ||
| Q2 25 | — | -440.1% | ||
| Q1 25 | — | -4503.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -1223.3% | — | ||
| Q3 25 | — | -1532.9% | ||
| Q2 25 | — | -785.1% | ||
| Q1 25 | — | -5174.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-0.10 | — | ||
| Q3 25 | $-0.13 | $-0.16 | ||
| Q2 25 | $-0.11 | $-0.16 | ||
| Q1 25 | $-0.15 | $-0.77 | ||
| Q4 24 | $0.88 | — | ||
| Q3 24 | $-0.65 | — | ||
| Q2 24 | $-0.66 | — | ||
| Q1 24 | $-0.73 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.3M | — |
| Total DebtLower is stronger | — | $17.7M |
| Stockholders' EquityBook value | $172.9M | — |
| Total Assets | $181.2M | $5.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.3M | — | ||
| Q3 25 | $39.1M | — | ||
| Q2 25 | $9.9M | — | ||
| Q1 25 | $19.7M | — | ||
| Q4 24 | $138.6M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $4.9M | — | ||
| Q1 24 | $7.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $17.7M | ||
| Q1 25 | — | $17.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $172.9M | — | ||
| Q3 25 | $72.9M | — | ||
| Q2 25 | $80.1M | — | ||
| Q1 25 | $85.7M | — | ||
| Q4 24 | $94.9M | — | ||
| Q3 24 | $-530.6K | — | ||
| Q2 24 | $5.1M | — | ||
| Q1 24 | $6.8M | — |
| Q4 25 | $181.2M | — | ||
| Q3 25 | $79.6M | $5.1M | ||
| Q2 25 | $88.9M | $4.6M | ||
| Q1 25 | $94.3M | $5.1M | ||
| Q4 24 | $98.6M | — | ||
| Q3 24 | $4.4M | — | ||
| Q2 24 | $8.8M | — | ||
| Q1 24 | $11.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.5M | $-758.5K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.5M | — | ||
| Q3 25 | $-10.6M | $-758.5K | ||
| Q2 25 | $-5.6M | $-1.5M | ||
| Q1 25 | $-4.1M | $-2.2M | ||
| Q4 24 | $-5.3M | — | ||
| Q3 24 | $-4.9M | — | ||
| Q2 24 | $-5.1M | — | ||
| Q1 24 | $-3.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | $-4.1M | $-2.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -166.0% | ||
| Q1 25 | — | -623.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
